Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University in Baltimore, Maryland, and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

A post hoc analysis of OLYMPIA 1 and 2 trial data found significant improvement in the first 14 days of treatment.

Nemolizumab Delivers Rapid Itch Response in Patients with PN

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

The target action review date has been pushed to March 12, 2025.

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

Quality of Life Severely Affected for Patients with GPP

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives. 

Benzene Concerns in Benzoyl Peroxide Spark Calls for Safer Acne Treatment Standards 

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Bob Rhatigan, CEO of Merz Aesthetics, discusses the organization’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

Expanding Innovation and Education in Medical Aesthetics

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

SkylineDx, an oncology biotechnology company, announced new data from the MERLIN__001 trial, confirming the validity and efficacy of the Merlin test in identifying sentinel lymph node biopsy (SLNB) status in patients with melanoma.

The prospective US multi-center trial is the largest ever conducted to assess the performance of a genomic test for melanoma.

The first results from the study were presented at the 2024 Society for Melanoma Research Congress from October 10 to 13 in New Orleans, Louisiana.

The trial was performed at 9 academic sites in the US. It included 1686 patients with melanoma (T1-T3) who underwent SLNB. Patients were classified as “High Risk” or “Low Risk.” Overall, 37% of participants were in the low-risk category. Among these, only 7.1% had a positive SLN. This resulted in a negative predictive value of 92.9%. Conversely, 23.8% of patients deemed “High Risk” patients had positive SLNs.

The study also took a closer look at T1a, with the goal of avoiding overtreatment for early-stage melanoma. Patients with low-risk T1 melanoma (88%) had a post-test SLN positivity rate of only 1.5%. In contrast, 12% of patients were classified as high-risk with a higher SLN positivity rate of 15.8%.

Several patients with adverse features were also tested, including patients under age 40, those with lymph vascular invasion, and those with a high mitotic rate. These 37 patients were categorized in the low-risk group, with a post-test SLN positivity rate of 0%. Additionally, 7 patients without any adverse features were identified as high-risk (SLN positivity rate of 14.3%).

"The intent is to help prevent undertreatment in seemingly low-risk early-stage melanoma patients who are actually at risk for nodal metastasis,” Alexander Meves, MD, MBA, dermatologist at Mayo Clinic and principal inventor of the CP-GEP model, shared in a statement. “By accurately identifying these at-risk individuals, we ensure that they receive the necessary interventions, even in the absence of traditional clinical risk factors."

The CP-GEP (clinical pathologic and gene expression profiling) Merlin model was developed by Mayo Clinic and SkylineDx BV and has already been launched in the US and Europe. Validated with an overall sentinel lymph node positivity rate of over 17%, CP-GEP is an accurate, non-invasive procedure that categorizes patients with melanoma as being at high or low risk for metastasis. The results can guide clinicians in choosing the most appropriate actions for prevention, screening, and SLNB treatment.

SLNB is a common procedure often recommended for patients with a predicted metastasis risk of >10%. However, because more than 80% of these procedures reveal no metastasis, patients experience increased risk of complications and costs, without realizing therapeutic benefit. The Merlin test allows surgeons to explore less aggressive treatment plans and improve overall patient care.

Vernon Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center and 1 of 3 principal investigators for this study, noted the results were significant for patient care.

"This landmark trial will allow us to have more informed conversations with our patients about their surgical treatment options,” Sondak said in a press statement. “These results provide critical insights for clinicians, allowing us to move toward more precise and individualized care."

Editor's note courtesy of Aaron Farberg, MD, as of 10/30/24

: The CP-GEP Merlin Test test was designed to predict patients with less than a 5% risk of a positive sentinel lymph node. That 5% is the current standard of care by NCCN guidelines. The study was designed with the hypothesis that the test could predict patients with less than 5% positivity. Their outcome was that the test predicts patients with 7% risk, which makes it inadequate compared to our current standard of care.]

1. Hieken TJ, Egger ME, Angeles CV, et al. MERLIN_001: A prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of patients with sn-negative melanoma. 

 2022;40(16_suppl). doi:10.1200/jco.2022.40.16_suppl.tps9606

2. SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at 21st International Congress of the Society for Melanoma Research. SkylineDx. Published October 13, 2024. 

https://www.prnewswire.com/news-releases/skylinedx-announces-data-from-largest-prospective-multi-center-melanoma-gene-expression-profiling-trial-at-21st-international-congress-of-the-society-for-melanoma-research-302274550.html

3. SkylineDx Announces Presentation of New Data Highlighting the Predictive Power of the CP-GEP Merlin Test for T1a Cutaneous Melanoma Patients at the 21st International Congress of the Society for Melanoma Research. SkylineDx. Published October 11, 2024. 

https://www.prnewswire.com/news-releases/skylinedx-announces-presentation-of-new-data-highlighting-the-predictive-power-of-the-cp-gep-merlin-test-for-t1a-cutaneous-melanoma-patients-at-the-21st-international-congress-of-the-society-for-melanoma-research-302273871.html

SkylineDx's MERLIN__001 trial validates the Merlin test's efficacy in predicting sentinel lymph node biopsy (SLNB) status in melanoma patients. Conducted across nine US academic sites, the trial involved 1686 patients, classifying them as "High Risk" or "Low Risk" for SLN positivity. The CP-GEP Merlin model, developed by Mayo Clinic and SkylineDx, offers a non-invasive method to identify patients at risk for metastasis, potentially reducing unnecessary SLNB procedures. This approach aims to enhance patient care by enabling more precise and individualized treatment strategies.

Results from Society for Melanoma Research Congress demonstrated excellent predictive power of noninvasive CP-GEP Merlin test.

SkylineDx Data Confirms Accuracy of the Merlin Test for Low- and High-Risk Melanoma 

Moderna and Merck recently announced new results

 from a planned analysis from the phase 2b randomized KEYNOTE-942 clinical trial (

) evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with pembrolizumab (Keytruda), Merck’s anti-PD-1 therapy, in patients with resected high-risk stage III/IV melanoma following complete resection (n=157). After a median follow-up of 3 years (34.9 months), adjuvant treatment with mRNA-4157 in combination with pembrolizumab continued to show a clinically meaningful and durable improvement in the primary end point of recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR [95%CI], 0.510 [0.288–0.906]), compared with pembrolizumab as monotherapy.

The combination of mRNA-4157 and pembrolizumab also demonstrated a meaningful improvement in one of the key secondary end points of distant metastasis-free survival (DMFS), compared to pembrolizumab as monotherapy, therefore reducing the risk of developing distant metastasis or death by 62% (HR [95% CI], 0.384 [0.172–0.858]).

The new 3-year data on mRNA-4157 and pembrolizumab was presented at the 2024 American Society of Clinical Oncology Annual Meeting. According to the news announcement, an additional year of follow-up is planned, adding to the earlier analyses of the primary and secondary end points.

Based on continued positive data, Merck and Moderna have initiated a phase 3 randomized clinical trial evaluating mRNA-4157 combined with pembrolizumab as an adjuvant treatment in patients with resected high-risk (stage IIB-IV) melanoma (INTerpath-001, 

), which is actively enrolling participants.

“We are encouraged by the latest results from the KEYNOTE-942/mRNA-4157-P201 study. These data highlight the sustained benefit in RFS and DMFS of mRNA-4157 (V940) as adjuvant treatment in combination with KEYTRUDA in people with resected high-risk melanoma. Importantly, this benefit was observed across various patient exploratory subgroups, reflecting the potential of mRNA-4157 (V940) for a broad range of these patients,” said Kyle Holen, MD, senior vice president and head of development of therapeutics and oncology at Moderna, in the news release. “These findings reinforce our commitment to advancing this innovative treatment in collaboration with Merck, and we are dedicated to harnessing mRNA technology to potentially transform cancer therapy and improve patient outcomes.”

The previous 2.5-year RFS rate of mRNA-4157 plus pembrolizumab was 74.8%, as compared to 55.6% for pembrolizumab as monotherapy, with the benefit observed across exploratory subgroups.

“The sustained improvements in recurrence-free survival and distant metastasis-free survival observed at approximately three years in the KEYNOTE-942/mRNA-4157-P201 study provide further support of the potential of mRNA-4157 (V940) in combination with KEYTRUDA to help patients with resected high-risk melanoma,” said Marjorie Green, MD, senior vice president and head of oncology and global clinical development at Merck Research Laboratories, in the news release. “We look forward to building on our legacy of turning breakthrough science into medicines that may have a meaningful impact on patients’ lives as we continue advancing our broad clinical development program evaluating this novel approach with Moderna.”

Additional data from an exploratory subgroup analysis of KEYNOTE-942 in patients with resected high-risk stage III/IV melanoma following complete resection showed that improvement in RFS was seen with mRNA-4157 plus pembrolizumab compared to pembrolizumab as monotherapy regardless of tumor mutational burden (TMB) or programmed death-ligand 1 (PD-L1) status.

The RFS benefit of mRNA-4157 plus pembrolizumab compared to pembrolizumab as monotherapy was maintained across both TMB high (HR [95% CI], 0.564 [0.253–1.258]), TMB non-high (0.571 [0.245–1.331]), PD-L1 positive (0.471 [0.226–0.979]), PD-L1 negative (0.147 [0.034–0.630]), and circulating tumor DNA (ctDNA) negative (0.207 [0.091–0.470]) subpopulations. Additionally, data could not be collected on ctDNA-positive HR due to the small sample size. There were no significant associations between individual human leukocyte antigen alleles and RFS observed for mRNA-4157 plus pembrolizumab.

The exploratory end point of overall survival (OS) favored mRNA-4157 plus pembrolizumab compared to pembrolizumab as monotherapy, with a 2.5-year OSrate of 96.0% vs. 90.2%, respectively (HR [95% CI], 0.425 [0.114–1.584]). The most common adverse events attributed to mRNA-4157 plus pembrolizumab were fatigue (60.6%), injection site pain (56.7%), and chills (49.0%).

1. Moderna & Merck announce 3-year data for mRNA-4157 (v940) in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in recurrence-free survival & distant metastasis-free survival versus KEYTRUDA in patients with high-risk stage III/IV melanoma following complete resection. News release. Merck. June 3, 2024. Accessed June 3, 2024. 

https://www.merck.com/news/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su/

Moderna and Merck's phase 2b KEYNOTE-942 trial results reveal that mRNA-4157 combined with pembrolizumab significantly improves recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in high-risk stage III/IV melanoma patients post-resection. The combination therapy reduced recurrence or death risk by 49% and distant metastasis or death risk by 62% compared to pembrolizumab alone. These benefits were consistent across various subgroups, regardless of tumor mutational burden or PD-L1 status. A phase 3 trial is underway to further evaluate this promising adjuvant treatment.

Phase 3 trials have been initiated in patients with high-risk melanoma. 

Moderna and Merck Announce New 3-Year Data for mRNA-4157 Combined With Pembrolizumab for High-Risk Stage III/IV Melanoma 

Photodynamic Pearls and Best Practices

I'm sorry, but it seems that there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Monica Boen, MD, discusses how implementing proven photodynamic therapy techniques and adhering to best practices can significantly improve treatment outcomes and patient satisfaction.

  Making PDT Adjustments and Maintaining Patient Flow

I'm sorry, but it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Monica Boen, MD, discusses how optimizing photodynamic therapy protocols and streamlining patient scheduling can enhance treatment efficiency and maintain steady patient flow in clinical settings.

Making PDT Adjustments and Maintaining Patient Flow

 in Las Vegas, Nevada, from October 24 to 27, a poster was presented demonstrating the efficacy of the novel 

 treatment for active non-segmental vitiligo (aNSV)

. These results come from a phase 1b clinical trial testing the use of VYN201 at various dosage levels. According to the study team at VYNE Therapeutics, these findings confirm the safety and tolerability of the topical gel for aNSV.

VYN201 is a topical small molecule BET (bromodomain and extra-terminal domain) inhibitor that minimizes disease severity and encourages anti-inflammatory effects. Pre-clinical trials observed that the treatment inhibits CD8+ T-cell expansion without being cytotoxic and prevents detachment and melanin loss from the basal layers of tissue. Researchers saw a significant reduction in the release of MMP-9 (

 ≤ 0.01). These pre-evaluations were also presented through a poster at this year’s Fall Clinical.

“VYN201 represents a differentiated potential treatment for aNSV, as it down-regulates vitiligo markers, up-regulates melanogenesis factors, prevents continued depigmentation in patients, and shows evidence of re-pigmentation,” the investigators noted.

The phase 1b, open-label, multi-center study took place over 16+ weeks with 28 days of screening, 112 days of outpatient treatment, and 7 days of safety follow-up. Patients were split into 3 dose cohorts of 0.5% (

 = 9). The topical treatment was applied once daily on affected skin not exceeding 10% of body surface area.

The 29 participants were between the ages of 18 and 75 and had been clinically diagnosed with aNSV for at least 1 month. Eligibility also included having a Facial Vitiligo Area and Severity Index Score (F-VASI) of ≥ 0.5 with active vitiligo on the face. Active lesions were defined as having hypochromic borders, confetti-like depigmentation, peri-lesional inflammation, and/or Koebner phenomenon.

All 3 dosage cohorts had significant clinical response after 16 weeks of multiple-dose administration. Participants with the 0.5% dose experienced a -7.5% change in F-VASI scores while there was a -30.2% change in F-VASI for the 1% dosage group. Ultimately, the 2% dose group experienced the most drastic change in F-VASI score at -39.0%. The poster also featured patient photographs taken before and after treatment, including a participant with near-complete depigmentation.

Additionally, the mean scores of localized skin tolerance assessments (LSTA) did not increase over the course of the 16-week treatment. Although there were some mild to moderate adverse effects such as erythema, stinging, and dryness, no serious events occurred and none of these TEAEs led to treatment discontinuation. There were also no clinically relevant localized skin tolerability findings.

Through this study, researchers confirmed that patients treated with VYN201 saw a significant dose-dependent clinical response by the 16-week mark. The topical delivery enabled local anti-inflammatory effects and minimized systemic exposure while maintaining a strong safety profile.

"This disease state has had marked, marked unmet need for many, many years. It has been overlooked by industry with respect to new therapies, and even the therapies that are coming through now are all based on one pharmacology," Iain Stuart, PhD, the chief scientific officer at VYNE said in an 

. "We think that's unacceptable. We think the potential for BET inhibition could be very broad, and not just in vitiligo, but into all the dermatologic and immunologic diseases. We're looking forward to continuing the program and involving the dermatology community in the next steps for VYN201."

1. Stuart I. Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo.Poster presented at the 44th Annual Fall Clinical Dermatology Conference. Las Vegas, Nevada. October 24 to 27, 2024.

2. Stuart I. Preclinical studies: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo. Poster presented at the 44th Annual Fall Clinical Dermatology Conference. Las Vegas, Nevada. October 24 to 27, 2024.

3. Andrus E, Stuart I. VYN201 for vitiligo: promising data showcases potential of BET inhibition. Dermatology Times. May 22, 2024. Accessed November 1, 2024. 

https://www.dermatologytimes.com/view/vyn201-for-vitiligo-promising-data-showcases-potential-of-bet-inhibition

A phase 1b clinical trial presented at Fall Clinical 2024 demonstrated the efficacy and safety of VYN201, a topical BET inhibitor, for treating active non-segmental vitiligo (aNSV). The study involved 29 participants across three dosage cohorts, showing significant dose-dependent clinical responses in F-VASI scores over 16 weeks. VYN201 effectively down-regulated vitiligo markers, up-regulated melanogenesis factors, and prevented depigmentation. The treatment was well-tolerated with no serious adverse events. Researchers highlighted the potential of BET inhibition for broader dermatologic and immunologic applications.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Bob Rhatigan

Articles

Latest Updated Articles